ProKidney Corp
PROK
View Detailed Chart
2.710USD
+0.180+7.11%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
361.57MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+7.11%
5 Days
-9.06%
1 Month
+6.69%
6 Months
+179.50%
Year to Date
+60.36%
1 Year
+13.39%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-18Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
5.833
Target Price
+130.57%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Growing
The company is in a growing phase, with the latest annual income totaling USD 76.00K.
Fairly Valued
The company’s latest PE is -4.84, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 92.52M shares, decreasing 11.64% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.57M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.16.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Ticker SymbolPROK
CompanyProKidney Corp
CEODr. Bruce Culleton, M.D.
Websitehttps://prokidney.com/
Related Instruments
-0.35%
-4.12%
+3.22%
+1.88%
+0.75%
-1.87%
+0.72%
+6.30%
+0.83%
+2.41%
-0.11%
+0.02%
+2.31%
+0.70%
+2.93%
+0.93%
+5.59%
+3.22%
0.00%
+2.85%
